Table 1.
Characteristics of 8241 patients meeting the definition of U status (i.e. a HIV-RNA ≤200 copies/ml) in the ICONA cohort.
| Total | 90% or less time | More than 90% time | P valueb | |
| (N = 8241) | (N = 617) | (N = 7624) | ||
| Female [n (%)] | 1648 (20.0%) | 212 (34.4%) | 1436 (18.8%) | <0.001 |
| Agea (years) | 39 (31--47) | 39 (32--47) | 39 (30--47) | 0.435 |
| Mode of HIV transmission [n (%)] | <0.001 | |||
| PWID | 768 (9.3%) | 115 (18.6%) | 653 (8.6%) | |
| MSM | 3786 (45.9%) | 173 (28.0%) | 3613 (47.4%) | |
| Heterosexual contacts | 3176 (38.5%) | 289 (46.8%) | 2887 (37.9%) | |
| Foreign-born [n (%)] | 2066 (25.1%) | 190 (30.8%) | 1876 (24.6%) | <0.001 |
| Education [n (%)] | <0.001 | |||
| Primary school | 426 (5.2%) | 59 (9.6%) | 367 (4.8%) | |
| Secondary school | 1629 (19.8%) | 164 (26.6%) | 1465 (19.2%) | |
| College | 2579 (31.3%) | 161 (26.1%) | 2418 (31.7%) | |
| University | 1019 (12.4%) | 45 (7.3%) | 974 (12.8%) | |
| Employment [n (%)] | <0.001 | |||
| Unemployed | 952 (14.0%) | 123 (23.5%) | 829 (13.2%) | |
| Employed | 3488 (51.4%) | 226 (43.2%) | 3262 (52.0%) | |
| Self-employed | 1187 (17.5%) | 69 (13.2%) | 1118 (17.8%) | |
| HbsAg+ [n (%)] | 108 (1.3%) | 8 (1.3%) | 100 (1.3%) | 0.716 |
| HCVAb+ [n (%)] | 905 (11.0%) | 128 (20.7%) | 777 (10.2%) | <0.001 |
| Diabetes [n (%)] | 231 (2.8%) | 26 (4.2%) | 205 (2.7%) | 0.027 |
| Smoking [n (%)] | 2939 (35.7%) | 253 (41.0%) | 2686 (35.2%) | 0.004 |
| CVD diagnosis [n (%)] | 87 (1.1%) | 13 (2.1%) | 74 (1.0%) | 0.008 |
| Prior STDs | 1862 (22.6%) | 144 (23.3%) | 1725 (22.6%) | <0.001 |
| AIDS diagnosis [n (%)] | 1009 (12.2%) | 110 (17.8%) | 899 (11.8%) | <0.001 |
| CD4+ cell counta (cells/μl) | 532 (356--730) | 507 (302--698) | 534 (361--733) | <0.001 |
| CD4+ cell count nadira (cells/μl) | 300 (162--436) | 264 (119--403) | 302 (166--438) | <0.001 |
| CD8+ cell counta (cells/μl) | 878 (633--1198) | 900 (661--1244) | 874 (632--1195) | 0.111 |
| Peak viral load in follow-upa (log10 copies/ml) | 4.52 (3.67--5.12) | 4.81 (4.16--5.35) | 4.49 (3.63--5.11) | <0.001 |
| CD4+ cell count ≤200 (cells/μl) [n (%)] | 824 (10.0%) | 94 (15.2%) | 730 (9.6%) | <0.001 |
| Time from HIV diagnosisa months | 15 (7--65) | 31 (9--115) | 14 (7--61) | <0.001 |
| Follow-up timea (months) | 45 (21--78) | 58 (30--82) | 44 (20--78) | <0.001 |
| No previous VF [n (%)] | <0.001 | |||
| 1–3 | 429 (5.2%) | 54 (8.8%) | 375 (4.9%) | |
| 3+ | 324 (3.9%) | 65 (10.5%) | 259 (3.4%) |
ART, antiretroviral therapy; CVD, cardiovascular disease; PWID, people who inject drug; STDs, sexual transmitted diseases; VF, virologic failure.
a
Median (IQR).
b
Chi-square or Mann--Whitney U test as appropriate.